Shalini Sharp

Chief Financial Officer and Executive Vice President

Ms. Sharp joined Ultragenyx in May 2012 as Chief Financial Officer. She is responsible for leading the corporate finance, strategy, and information technology functions and is a member of the company’s executive leadership team. Ms. Sharp has over twenty years of experience in the life sciences industry.

Ms. Sharp is a member of the Board of Directors of Array Biopharma, a publicly traded biotechnology firm focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. She is also a member of the Board of Directors of the TB Alliance, a non-profit organization dedicated to the development and distribution of treatments for tuberculosis in the developing world.

Prior to Ultragenyx, Ms. Sharp was Chief Financial Officer of Agenus Inc., a publicly traded biotechnology company focused on cancer immunotherapies from 2006 to 2012 and served on the Board of Agenus from 2012 to 2018. She joined Agenus in 2003 and held increasing roles of responsibility spanning strategic planning, corporate development, investor relations, corporate finance and business development. Prior to Agenus, Ms. Sharp held similar roles at Elan Pharmaceuticals from 1998 to 2003, including serving as chief of staff to the Chairman of the Board of Directors during that company's restructuring. Ms. Sharp was also a management consultant at McKinsey & Company as well as an investment banker at Goldman Sachs, specializing in pharmaceuticals and medical devices.

Ms. Sharp holds both a B.A., magna cum laude, and M.B.A., from Harvard University.